Anti-drug antibodies and rheumatoid factor level in patients with rheumatoid arthritis using the infliximab biosimilar CT-P13

Abstract Background This study evaluated the existence of anti-drug antibodies (ADAs) before and 52 weeks after switching from intravenous infliximab (IFX) to intravenous CT-P13 in patients with rheumatoid arthritis (RA). Methods We performed a prospective observational study. Twenty-eight patients...

Descripció completa

Dades bibliogràfiques

Autors principals:	Hideo Sakane, Koichi Okamura, Makoto Inoue, Hiroshi Inoue, Yukio Yonemoto, Hirofumi Mitomi, Kosei Tsuchida, Takahito Suto, Tetsuya Kaneko, Hirotaka Chikuda
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2022-12-01
Col·lecció:	BMC Rheumatology
Matèries:	Anti-drug antibody Biosimilar CT-P13 Infliximab Rheumatoid factor
Accés en línia:	https://doi.org/10.1186/s41927-022-00304-9
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!